Product Description: Taltrimide (MY-117), a lipophilic derivative of Taurine (HY-B0351), strongly inhibits the sodium-independent binding of Taurine to synaptic membranes of brain, the effects on the binding of GABA being less pronounced. Taltrimide exhibits definitive anticonvulsive effects in experimental epilepsy models[1][2][3].
Formula: C13H16N2O4S
References: [1]Airaksinen EM, et, al. Biochemical and clinical studies on epileptic patients during two phase I trials with the novel anticonvulsant taltrimide. Epilepsy Res. 1987 Sep;1(5):308-11./[2]Keränen T, et, al. Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients. Epilepsia. 1987 Mar-Apr;28(2):133-7./[3]Kontro P, et, al. Effects of the anticonvulsant taurine derivative, taltrimide, on membrane transport and binding of GABA and taurine in the mouse cerebrum. Neuropharmacology. 1987 Jan;26(1):19-23.
CAS Number: 81428-04-8
Molecular Weight: 296.34
Compound Purity: 0.9
Research Area: Neurological Disease
Target: Drug Derivative
Deutsch
English
